This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Lysergic acid diethylamide (LSD) in anxiety

Authoring team

Lysergic acid diethylamide (LSD) is a well-known classic psychedelic substance:

  • psychedelics, including LSD and psilocybin, induce profound acute alterations of mind and mystical-type experiences primarily by interacting with the serotonin 5-HT2A receptor
  • the use of LSD in the management of anxiety was investigated in an investigator-initiated 2-centre trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period (1)
    • the primary endpoint was anxiety symptoms 16 weeks after the last treatment session
    • showed that LSD produced long-lasting and notable reductions in anxiety and comorbid depression symptoms up to 16 weeks

Reference:

  1. Holze F, Gasser P, Müller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023 Feb 1;93(3):215-223.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.